United Therapeutics Corp. Given New $75.00 Price Target at Credit Suisse (UTHR)
Credit Suisse increased their price objective on shares of United Therapeutics Corp. (NASDAQ:UTHR) to $75.00 in a research note issued on Wednesday, American Banking News reports. Credit Suisse’s target price would indicate a potential downside of 8.25% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Zacks upgraded shares of United Therapeutics Corp. from a “neutral” rating to an “outperform” rating in a research note to investors on Monday, October 7th. They now have a $103.00 price target on the stock. Separately, analysts at Goldman Sachs Group Inc. raised their price target on shares of United Therapeutics Corp. from $55.00 to $56.00 in a research note to investors on Wednesday, September 18th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $67.18.
In other United Therapeutics Corp. news, CEO Martine Rothblatt unloaded 3,833 shares of United Therapeutics Corp. stock on the open market in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $82.58, for a total value of $316,529.14. Following the completion of the transaction, the chief executive officer now directly owns 140 shares in the company, valued at approximately $11,561. The transaction was disclosed in a document filed with the SEC, which is available at this link.
United Therapeutics Corp. (NASDAQ:UTHR) traded up 1.30% during mid-day trading on Wednesday, hitting $81.74. 565,143 shares of the company’s stock traded hands. United Therapeutics Corp. has a 1-year low of $44.51 and a 1-year high of $85.92. The stock has a 50-day moving average of $78.20 and a 200-day moving average of $69.84. The company has a market cap of $4.081 billion and a price-to-earnings ratio of 13.91.
United Therapeutics Corp. (NASDAQ:UTHR) last posted its quarterly earnings results on Thursday, July 25th. The company reported $1.52 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.47 by $0.05. The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $250.17 million. During the same quarter last year, the company posted $1.34 earnings per share. United Therapeutics Corp.’s revenue was up 24.4% compared to the same quarter last year. Analysts expect that United Therapeutics Corp. will post $5.99 EPS for the current fiscal year.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.